Pharma Pulse 5/16/25: A Closer Look at NIH Grant Terminations; Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

A Closer Look at NIH Grant Terminations

In an interview with Applied Clinical Trials, Harvard Medical School researcher Michael Liu discussed a recent study analyzing NIH grant terminations, revealing that 20% of the cuts affected early career training grants—critical to the biomedical research pipeline—and disproportionately impacted institutions and clinical trials serving marginalized populations.

Simulated Pre-Launch Market Evaluation in the Modern Pharmaceutical Industry

In an article for Pharmaceutical Executive, simulated pre-launch market evaluation is presented as a strategic imperative in 2025, enabling pharmaceutical companies to de-risk launches, optimize resource allocation, and tailor strategies by leveraging real-world data, AI, and advanced analytics to navigate evolving market, regulatory, and competitive dynamics.

Medication Meltdown: Unpacking Drug Shortages

Drug shortages—driven by supply chain disruptions, manufacturing issues, and systemic vulnerabilities—continue to strain healthcare systems, impacting patient care, increasing costs, and underscoring the need for coordinated, transparent management strategies and proactive policy reforms.

VC firm reveals plan for 30K-square-foot biotech incubator space in New Jersey

Venture capital firm Portal Innovations will open a 30,000-square-foot biotech incubator at New Jersey’s Helix NJ complex, aiming to boost the state’s life sciences sector by offering lab space, funding, and industry connections to local university entrepreneurs.

US FDA approves Amneal's self-administered migraine treatment

The FDA has approved Amneal Pharmaceuticals' Brekiya, a self-administered autoinjector delivering dihydroergotamine mesylate for acute migraine and cluster headache treatment in adults, offering a convenient, refrigeration-free alternative for patients who don’t respond well to oral therapies.